EDMONTON, Alberta--(BUSINESS WIRE)--Dec. 14, 2005--ViRexx Medical Corp. (TSX:VIR) a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, announced today that enrollment has been completed for the first of two identical Phase III trials for OvaRex(R) MAb, IMPACT I and IMPACT II. The IMPACT I Phase III trial reached its target enrollment of 177 patients with stage III/IV advanced ovarian cancer who have successfully completed front-line therapy.
